P11.14.A Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2021

Abstract Background Despite a plethora of studies since the EORTC/NCIC trial in 2005, glioblastoma (GBM) prognosis remains poor. We here identify and compare phase III trials terms efficacy baseline characteristics an attempt to summarize experience past 16 years. Methods A systematic literature search using PubMed ClinicalTrials.gov was conducted provide overview clinically relevant GBM (years 2005-2021) adult patients younger than 70 years age. Search results were screened according predefined inclusion criteria either excluded or included further analysis on study design, characteristics, survival results. Results Eleven from clinical database fulfilled criteria. Among these trials, total three reported overall (OS) benefit, including (NCT00006353), EF-14 (NCT00916409) CeTeG/NOA09 (NCT01149109). All demonstrate similar hazard ratios, which translate into risk reduction about 40%. Furthermore, low toxicity profile mostly preserved quality life attributed treatments tested. Looking at designs, eight out eleven open label randomized all positive ones, only negative employed treatment blinding placebo control. Canonical (extent resection, age, gender, MGMT promoter methylation status) did not significantly differ between trials. IDH mutation status analyzed two each showing small percentage IDH-mutant tumors only. Conclusion This 2005 2021 revealed that majority show significant improvement survival. CeTeG/NOA-09 are with outcome 2005.